Literature DB >> 19159911

[B lymphocytes: a new "target" in treatment for multiple sclerosis].

R Hohlfeld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19159911     DOI： 10.1007/s00115-008-2643-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  7 in total

Review 1.  B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation.

Authors:  Edgar Meinl; Markus Krumbholz; Reinhard Hohlfeld
Journal:  Ann Neurol       Date:  2006-06       Impact factor: 10.422

Review 2.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

Authors:  H Lassmann; W Brück; C Lucchinetti
Journal:  Trends Mol Med       Date:  2001-03       Impact factor: 11.951

Review 3.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

4.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

5.  Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.

Authors:  M Krumbholz; H Faber; F Steinmeyer; L-A Hoffmann; T Kümpfel; H Pellkofer; T Derfuss; C Ionescu; M Starck; C Hafner; R Hohlfeld; E Meinl
Journal:  Brain       Date:  2008-05-12       Impact factor: 13.501

6.  Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

Authors:  M Krumbholz; I Meinl; T Kümpfel; R Hohlfeld; E Meinl
Journal:  Neurology       Date:  2008-10-21       Impact factor: 9.910

Review 7.  The spectrum of neuromyelitis optica.

Authors:  Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.